Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate for Dry Eye Disease
NCT02218827Unknown
- Sponsor
- Meir Medical Center
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of loteprednol etabonate ophthalmic gel 0.38% in dry eye disease (DED), sponsored by Meir Medical Center. Primary endpoint: Clinical improvement in dry eye measurements at 2 months. Status: unknown.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02218827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218827.